BRD4 and diffuse large B-cell lymphoma: BET domain protein inhibitors downregulate genes with expression driven by BRD4‐dependent gene enhancers, and have activity against DLBCL cell lines in vitro and in vivo.189 They cannot really be viewed as precision therapy for DLBCL since there currently is no biomarker or genetic lesion that predicts for selective response to these agents, and their actions are fairly pleiotropic.